Carter v. Johnson & Johnson

CourtDistrict Court, D. Nevada
DecidedMarch 31, 2021
Docket2:20-cv-01232
StatusUnknown

This text of Carter v. Johnson & Johnson (Carter v. Johnson & Johnson) is published on Counsel Stack Legal Research, covering District Court, D. Nevada primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Carter v. Johnson & Johnson, (D. Nev. 2021).

Opinion

UNITED STATES DISTRICT COURT ° DISTRICT OF NEVADA □□ Ok

TAMARA CARTER, et al., Case No. 2:20-cv-1232-KJD-VCF Plaintiffs, ORDER v. 1 ETHICON, INC., et al., Defendants. 13 Presently before the Court is Defendants’ Motion for Summary Judgment (#73). Plaintiffs filed a response in opposition (#89) to which Defendants replied (#90/91). Also before ° the Court is Plaintiffs’ Motion for Partial Summary Judgment (#76). Defendants filed a response in opposition (#88). L Facts 18 Plaintiffs are citizens of the state of Nevada and all of Ms. Tamara Carter’s (“Carter”) treatment, as alleged in her amended Short Form Complaint, occurred in the state of Nevada. See ° Doc. No. 17. Carter was implanted with a Prolift Posterior and TVT-retropubic by Dr. Hsieh on I July 23, 2010. Prior to these implant surgeries, she complained of symptoms consistent with ° stress urinary incontinence and pelvic organ prolapse such as pelvic fullness and the sensation °° that the“bladder was falling out.” Carter experienced multiple mesh erosions following the ° implantation of the Prolift and TVT devices. °° On October 31, 2011 Carter returned to Dr. Hsieh and was found to have an erosion at ° posterior vaginal wall which was, tender to palpation. On November 30, 2011 Dr. Hsich trimmed ° the mesh exposure in the office and silver nitrate was applied to the region. On December 21, 2011, Carter returned to Dr. Hsieh complaining of heavy vaginal bleeding after sex and feeling mesh at the tip of the vagina near the opening. She also reported urinating 15 times per day. On

January 6, 2012, Dr. Hirsh performed a mesh extrusion repair, a surgical procedure, on Carter. In May of 2012, Dr. Schwartz evaluated Carter for complaints of mesh exposure, vaginal ; pain, and bleeding. The exam again demonstrated a mesh exposure on the posterior vaginal wall. Carter again underwent a surgery to remove portions of the mesh. An additional mesh erosion ° was noted by Dr. Schwartz on February 6, 2013. Another mesh exposure was seen on October 31, 2014, which required another visit to the operating room in January of 2015. Later the same year in May, Carter again had surgery to repair an additional area of exposed posterior mesh. Carter had another surgical procedure on July 23, 2015, for the treatment of an autologous fascial sling. She continues to complain of dyspareunia and urinary frequency. The physician who implanted Ms. Carter’s Prolift and TVT device testified that he had reviewed and relied upon both IFU’s prior to performing Ms. Carter’s surgery. Dr. Hsieh also testified that at the time of implant, he was not aware that the Prolift mesh could rope or curl, or 8 that there could be a chronic foreign body reaction from the mesh in the Prolift and TVT. IL, Standard for Summary Judgment The purpose of summary judgment is to avoid unnecessary trials by disposing of factually unsupported claims or defenses. Celotex Corp. v. Catrett, 477 U.S. 317, 323-24 (1986); Northwest Motorcycle Ass’n v. U.S. Dept. of Agriculture, 18 F.3d 1468, 1471 (9th Cir. 1994). It 8 is available only where the absence of material fact allows the Court to rule as a matter of law. Fed. R. Civ. P. 56(a); Celotex, 477 U.S. at 322. Rule 56 outlines a burden shifting approach to summary judgment. 2! First, the moving party must demonstrate the absence of a genuine issue of material fact. The burden then shifts to the nonmoving party to produce specific evidence of a genuine factual °3 dispute for trial. Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 U.S. 574, 587 (1986). A genuine issue of fact exists where the evidence could allow “a reasonable jury [to] return a verdict for the nonmoving party.” Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248 (1986). The Court views the evidence and draws all available inferences in the light most favorable to the nonmoving party. Kaiser Cement Corp. v. Fischbach & Moore, Inc., 793 F.2d 1100, 1103 (9th Cir. 1986). Yet, to survive summary judgment, the nonmoving party must show more than

-2-

“some metaphysical doubt as to the material facts.” Matsushita, 475 U.S. at 586. Il. Analysis ; A. Failure to Warn Nevada has adopted the learned intermediary doctrine. See Klasch v. Walgreen Co., 264 ° P.3d 1155, 1157-58 (Nev. 2011) (in the context of pharmacist/customer tort litigation). The Nevada Supreme Court relied upon the rationale for the traditional learned intermediary doctrine “used to insulate drug manufacturers from liability in products-liability lawsuits[, viz.,]...a drug manufacturer is immune from liability to a patient taking the manufacturer’s drug so long as the manufacturer has provided the patient’s doctor with all relevant safety information for that drug.” Id. at 1158. “It is then up to the patient’s doctor—who has the benefit of knowing the patient’s specific situation—to convey to the patient any information that the doctor deems relevant.” Id. 8 While the Nevada Supreme Court has yet to extend the learned intermediary doctrine to a prescription medical device action, the Federal District Court of Nevada has repeatedly done so, explaining that “[i]n the absence of case law to the contrary, the Court believes that the Nevada Supreme Court would apply the learned intermediary doctrine to prescription medical product liability cases.” Flowers v. Eli Lilly & Co., No. 3:14-cv-0094-LRH-VPC, 2015 U.S. Dist. LEXIS 8 91298, at *7, n.3 (D. Nev. July 10, 2015) (Hicks, J.); see also Phillips v. C.R. Bard, Inc.,No. 3:12-cv-00344-RCJ-WGC, 2014 U.S. Dist. LEXIS 174506, at *23 (D. Nev. Dec. 16, 2014) (Jones, J.); cf: Schmidt v. C.R. Bard, Inc., No. 2:11-CV-00978-PMP-PAL, 2013 U.S. Dist. 2! LEXIS 101963, at *4-5 (D. Nev. July 22, 2013) (Pro, J). This Court, too, predicts that the Nevada Supreme Court would apply the learned intermediary doctrine to a prescription medical °3 product. Thus, the question is whether Plaintiff Tamara Carter’s treating physician, Dr. Hsieh, was given an adequate warning of the risks involved in using the product at issue. Defendant argues that Plaintiffs cannot establish proximate causation between any alleged failure to warn and Ms. Carter’s claimed injury. Defendants argue that there is no duty to warn of dangers that are “generally known” by those to be warned, here, pelvic floor surgeons. See General Elec. Co. v. Bush, 498 P.2d 366,369 (citing Helene Curtis Industries, Inc. v. Pruitt,

-3-

385 F.2d 841, 858 (Sth Cir. 1967)) (“Warning need not be given against dangers which are generally known”), If the physician had knowledge of the risk, “then the alleged failure to warn 3 of the known risk is not considered a defect.” Bellew v. Ethicon, Inc., No. 2:13-CV-22473, 2014 WL 6886129, at *2 (S.D. W. Va. Nov. 24, 2014) (internal quotation omitted); see also Odom v. ° G. D. Searle & Co., 979 F.2d 1001,1003 (4th Cir.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Fyssakis v. Knight Equipment Corp.
826 P.2d 570 (Nevada Supreme Court, 1992)
General Electric Company v. Bush
498 P.2d 366 (Nevada Supreme Court, 1972)
Forest v. Vitek, Inc.
884 F. Supp. 378 (D. Nevada, 1993)
Forest v. E.I. DuPont De Nemours, & Co.
791 F. Supp. 1460 (D. Nevada, 1992)
Huskey v. Ethicon, Inc.
29 F. Supp. 3d 736 (S.D. West Virginia, 2014)
Sanchez v. Boston Scientific Corp.
38 F. Supp. 3d 727 (S.D. West Virginia, 2014)
Mitchell v. Miller
884 F. Supp. 2d 334 (W.D. Pennsylvania, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Carter v. Johnson & Johnson, Counsel Stack Legal Research, https://law.counselstack.com/opinion/carter-v-johnson-johnson-nvd-2021.